SCHEMBL20135685

SCHEMBL20135685

Cc1ccc2c(C3CCN(C(=O)c4ccc([C@@]5(C)NC(=O)NC5=O)cc4)CC3)c[nH]c2c1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.44
BRD4 O60885 1/20 0.44
ALDH1A1 P00352 1/20 0.44
POLB P06746 1/20 0.44
CREBBP Q92793 1/20 0.44
MAPK7 Q13164 3/20 0.40
IDO1 P14902 1/20 0.39
SPR P35270 6/20 0.39
MAPT P10636 1/20 0.39
HSD11B1 P28845 3/20 0.39
NOS3 P29474 1/20 0.37
NOS1 P29475 1/20 0.37
ADAM17 P78536 1/20 0.37
ADAMTS5 Q9UNA0 1/20 0.37
KDM1A O60341 1/20 0.37
HTR1A P08908 1/20 0.37
HTR1D P28221 1/20 0.37
HTR1B P28222 1/20 0.37
HTR1F P30939 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29688837 1.00 KDM4E (0.44) KDM4EBRD4ALDH1A1POLBCREBBP
SCHEMBL20135686 1.00 KDM4E (0.44) KDM4EBRD4ALDH1A1POLBCREBBP
SCHEMBL20135341 0.87 KDM4E (0.40) KDM4EBRD4ALDH1A1POLBCREBBP
SCHEMBL29688634 0.87 KDM4E (0.40) KDM4EBRD4ALDH1A1POLBCREBBP
SCHEMBL20135337 0.87 KDM4E (0.40) KDM4EBRD4ALDH1A1POLBCREBBP
SCHEMBL29688981 0.85 ADAM17 (0.43) ALDH1A1MAPK7ADAM17ADAMTS5
SCHEMBL20134999 0.85 ADAM17 (0.43) ALDH1A1MAPK7ADAM17ADAMTS5
SCHEMBL20135191 0.83 MAPK7 (0.39) POLBMAPK7ADAM17ADAMTS5
SCHEMBL20135192 0.83 MAPK7 (0.39) POLBMAPK7ADAM17ADAMTS5
SCHEMBL20791723 0.79 MMP2 (0.40) ALDH1A1MAPK7HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 KDM4E 725/4885BRD4 982/4885ALDH1A1 584/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 KDM4E 723/4885BRD4 1494/4885ALDH1A1 610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.